Addressing Challenges of High Dose Dry Powder Delivery: Formulation and Device Considerations
Costa E, Marques L, Saldanha S, Cristovao J, Ventura J.
Respiratory Drug Delivery 2023. Volume , 2023: 101-112.
Abstract:
High dose delivery to the lungs is gaining momentum to address a diversified array of diseases being treated via respiratory drug delivery, comprising a range of drug classes, spanning from less potent small molecules to biologics. Dry powder inhalers (DPIs) are the dosage form of choice for delivering high payloads to patients. Still there are opportunities for improvement in terms of ensuring that the formulation addresses the pharmacokinetic needs of the specific drug and indication, in close integration with the device, while ensuring maximum delivery efficiency and safety.
Herein, different high dose delivery platform approaches are discussed in terms of relative advantages and potential pitfalls, exemplified by case studies covering small molecules to biologics. The development of high dose crystalline formulations and high dose spray dried proteins, as well as the integration of high dose formulations with the device will be addressed.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
